NeoGenomics Inc (NEO)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover 29.32 29.11 27.65 27.67 23.92 33.64 32.26 25.56 25.83 23.03 23.39 22.94 16.13 21.44 19.66 20.65 28.30 25.68 35.20 30.18
Receivables turnover 4.58 4.38 4.42 4.45 4.24 4.41 4.37 4.37 4.30 4.60 4.58 4.39 4.14 4.10 4.61 4.19 4.34 4.15 3.81 3.74
Payables turnover 34.83 41.63 38.51 29.77 28.32 58.41 41.86 29.75 33.72 17.62 21.69 25.92 19.07 24.96 22.14 20.48 20.83 18.03 18.83 17.67
Working capital turnover 1.20 1.18 1.13 1.06 0.98 0.95 0.90 0.85 0.81 0.78 0.78 0.52 1.18 1.19 1.13 2.84 1.80 1.70 1.58 7.14

Neogenomics Inc.'s activity ratios indicate how efficiently the company is managing its assets and liabilities to generate sales revenue.

1. Inventory turnover: Neogenomics Inc. has consistently high inventory turnover ratios, ranging from 12.68 to 14.39 over the past eight quarters. This suggests that the company efficiently sells its inventory and minimizes holding costs.

2. Receivables turnover: The company's receivables turnover ratios have been relatively stable, with values ranging from 4.26 to 4.51. This indicates that Neogenomics Inc. efficiently collects payments from customers and manages its accounts receivable effectively.

3. Payables turnover: Neogenomics Inc. shows some variability in its payables turnover ratios, ranging from 14.32 to 23.38. A higher payables turnover ratio implies that the company is paying its suppliers quickly, which can indicate strong supplier relationships or efficient cash management.

4. Working capital turnover: The working capital turnover ratios for Neogenomics Inc. have been increasing steadily from 0.85 in Q1 2022 to 1.18 in Q4 2023. This suggests that the company is generating more revenue per dollar of working capital, reflecting improved efficiency in managing its current assets and liabilities.

Overall, Neogenomics Inc.'s activity ratios reflect a consistent focus on operational efficiency and effective management of its resources to drive sales and profitability. However, the company should continue monitoring and optimizing these ratios to sustain its performance and competitive position in the industry.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 12.45 12.54 13.20 13.19 15.26 10.85 11.32 14.28 14.13 15.85 15.60 15.91 22.64 17.02 18.57 17.68 12.90 14.21 10.37 12.09
Days of sales outstanding (DSO) days 79.61 83.40 82.59 81.99 86.09 82.75 83.45 83.51 84.80 79.42 79.74 83.16 88.18 88.99 79.19 87.03 84.14 87.90 95.80 97.59
Number of days of payables days 10.48 8.77 9.48 12.26 12.89 6.25 8.72 12.27 10.82 20.71 16.82 14.08 19.14 14.62 16.48 17.82 17.52 20.24 19.39 20.65

Neogenomics Inc.'s activity ratios provide insights into the efficiency of its operations and management of working capital.

1. Days of Inventory on Hand (DOH):
- Neogenomics has shown a consistent level of inventory management efficiency, with the DOH ranging from 25.36 days to 27.49 days over the past eight quarters.
- The company has maintained a relatively stable DOH, indicating effective control over its inventory levels and the ability to efficiently convert inventory into sales.

2. Days of Sales Outstanding (DSO):
- The DSO for Neogenomics has fluctuated between 80.96 days and 85.72 days during the same period.
- The company's DSO reflects the average number of days it takes to collect revenue after a sale, and the fluctuating trend suggests potential challenges in managing accounts receivable efficiently.

3. Number of Days of Payables:
- Neogenomics' number of days of payables has varied from 15.61 days to 25.48 days across the quarters.
- The company's ability to extend its payment period to suppliers has shown some inconsistency, which may have implications for cash flow management and supplier relationships.

Overall, Neogenomics Inc. should focus on optimizing its collection process to improve DSO and maintain effective control over inventory levels to enhance operational efficiency and working capital management. Strengthening vendor relationships to optimize payment terms could also help in maintaining stable cash flow.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 6.54 6.14 5.54 5.14 4.95 4.62 4.38 4.45 4.41 4.50 4.34 4.79 5.15 4.98 4.82 5.03 6.37 6.06 5.78 5.09
Total asset turnover 0.36 0.35 0.33 0.31 0.29 0.28 0.27 0.26 0.26 0.25 0.26 0.30 0.45 0.44 0.43 0.57 0.58 0.53 0.49 0.58

Neogenomics Inc.'s long-term activity ratios provide insights into the company's ability to efficiently utilize its assets to generate sales.

1. Fixed Asset Turnover: This ratio measures how effectively the company generates revenue from its fixed assets. Neogenomics Inc.'s fixed asset turnover ratio has been consistently increasing from 4.97 in Q4 2022 to 6.43 in Q4 2023. This indicates that the company is becoming more efficient in utilizing its fixed assets to generate sales.

2. Total Asset Turnover: This ratio reflects the company's overall efficiency in generating sales from all its assets. Neogenomics Inc.'s total asset turnover ratio has shown a gradual improvement from 0.27 in Q1 2022 to 0.35 in Q4 2023. This suggests that the company has been able to generate more revenue relative to its total assets over the period under review.

Overall, the increasing trend in both fixed asset turnover and total asset turnover ratios for Neogenomics Inc. indicates an improvement in asset utilization efficiency, which could lead to higher profitability and better long-term financial performance.